What we do Innova Captab Limited is an integrated Indian pharmaceutical company offering CDMO services, domestic and international branded generics, covering manufacturing, R&D, marketing and exports. |
Founded in 2,005 |
Market share Strong CDMO presence with 300+ clients; domestic branded generics reach 2,20,000+ touchpoints; exports to 60+ countries. |
Problem solved Provides cost-effective manufacturing solutions and addresses diverse healthcare needs through a wide product portfolio and global reach. |
Top clients or who we serve Pharmaceutical companies (B2B) and broad patient base via branded generics in India and international markets (B2C). |
Key management - |
Our journey and innovations Founded 2005; expanded manufacturing in Baddi (2006), Jammu plant (2025); IPO in 2023; acquired Sharon Bio-Medicine (2023); growing product portfolio to 3,700+. |
Where we operate India with plants in Himachal Pradesh, Jammu; exports across 60+ countries including UK, Canada and emerging markets. |
Top products or what we offer CDMO manufacturing (oral solids, injectables, syrups), domestic and international branded generics, formulation and API products. |
Top brands - |
Raw materials needed Pharmaceutical raw materials for tablets, capsules, injectables, ointments, and syrups. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue comprised of recurring manufacturing contracts and branded generics sales with strong recurring client relationships. |
Our industry position One of the preferred CDMO partners in India, strong domestic and growing international branded generics presence with high client retention. |
Financial highlights FY25 consolidated revenue ₹1,244 Cr (+15%), EBITDA ₹198 Cr (15.9%), PAT ₹128 Cr (10.3%). |
Geographical revenue split Approximately 74% revenue from India, 26% from outside India. |
Order book - |
Whats driving growth Capacity expansions, new Jammu plant, increasing product portfolio and geographic expansion in branded generics fuel growth. |
Our future plans Scale Jammu facility utilization, set up R&D center in Panchkula, and explore further geographic and product expansions. |
Our green promise - |
Our people and values 1,950 employees, focus on health, diversity with ongoing efforts to improve gender ratio and employee engagement. |
Key challenges ahead Competitive pharmaceutical landscape, regulatory compliance, supply chain management, and scaling new facilities efficiently. |
Interesting facts New Jammu facility benefits from GST linked incentives and capital interest subvention; GMP certifications by UK MHRA and PIC/s Ukraine. |
Risks and strategy Manages risks via diversified client base, regulatory compliance framework, alternative raw material suppliers, and strong governance. |
